Last updated: 2026-09-09 04:21:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Veru Inc. (VERU) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.57, with a market capitalization of $45.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.05 to $7.33. This page covers its latest market performance, valuation, price trends and company information.
$45.01M | |
$2.81 | |
$245.70 | |
$2.05 | |
$2.64 | |
1.32M | |
375.10K | |
-- | |
$7.33 | |
$2.05 | |
-- | |
-- |
Veru Inc. (VERU) last closed at $2.64 as of 2026-09-09 00:00:00, unchanged from the previous close of $2.64.
During the latest regular trading session, VERU traded between $2.05 and $245.70, with a volume of 1.32M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Veru Inc. (VERU) moved from $2.74 to $2.57, representing a decline of 6.13% ($0.17).
The stock traded between $2.55 and $2.93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 155.81 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 9.9%
VERU is currently trading at $2.57, placing it 9.9% of the way from its 52-week low of $2.05 to its 52-week high of $7.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Veru Inc. (VERU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.